Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis

Author(s): Qin Fan, Wenhao Lv, Yuexin Xu, Yuan Dong, Zhiqiang Xiang, Junjie Wang*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 26 , 2020

Become EABM
Become Reviewer

Abstract:

Background: Metastatic colorectal cancer (mCRC) is one of the most common and deadly cancers worldwide. For most patients diagnosed with mCRC and managed with 5-fluorouracil (5-FU)/leucovorin plus oxaliplatin (FOLFOX), the median survival time is still less than 2 years. Small molecule selective vascular endothelial growth factor receptor (VEGFR) inhibitors have been demonstrated to have strong anti-tumour activity in various cancer models.

Objective: To demonstrate the efficacy and safety of selective VEGFR inhibitors in the management of mCRC.

Methods: A comprehensive search in PubMed, EMBASE, Web of Science, Ovid MEDLINE, Google Scholar, Springer and Cochrane Central databases was performed for randomized controlled trials (RCTs) focusing on the effect of selective VEGFR inhibitors on mCRC. The primary outcome measures were progression-free survival (PFS) rates, overall survival (OS) rates, complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rates (ORRs), disease control rates (DCRs) and adverse effect (AE) rates. The dates of the included studies ranged from the inception of the database to January 15, 2020.

Results: Twenty-two RCTs were included. A total of 9362 patients met the inclusion criteria. Compared with placebo, selective VEGFR inhibitors significantly increased the PFS rate, SD, PR and DCR, reduced PD, caused more treatment-emergent adverse events (TEAEs), hypertension, hand-foot skin reaction, diarrhoea, fatigue, and thrombocytopaenia and increased aspartate aminotransferase(AST) concentration. There was no significant difference between selective VEGFR inhibitors and placebo regarding OS rate, CR, ORR, proteinuria, hyperbilirubinaemia or alkaline phosphatase(ALP) concentration. Additionally, compared with FOLFOX4+placebo, FOLFOX4+ selective VEGFR inhibitors, clearly reduced PD, and caused more 3-4 AEs, serious AEs, hypertension, hand-foot syndrome, diarrhoea, nausea, vomiting, decreased appetite, dehydration, fatigue, dizziness, neutropaenia and thrombocytopaenia. For PFS rate, OS rate, CR, PR, SD, ORR, abdominal pain, peripheral sensory neuropathy, asthaenia, anaemia and hypokalaemia rates, there was no significant difference between FOLFOX4+ selective VEGFR inhibitors and FOLFOX4+placebo. However, compared with FOLFOX4+bevacizumab, FOLFOX4+selective VEGFR inhibitors, led to increased hypertension, neutropaenia, fatigue, thrombocytopaenia and asthaenia. There is no clear difference between FOLFOX4+selective VEGFR inhibitors and FOLFOX4+ bevacizumab with regard to PFS rate, OS rate, CR, PR, SD, PD, ORR, diarrhoea, nausea, vomiting, peripheral neuropathy and abdominal pain rates. Selective VEGFR inhibitors+cetuximab increased PFS and PR and reduced PD compared to cetuximab, but there was no statistical difference between the two groups for OS and SD.

Conclusion: Compared with placebo or cetuximab, selective VEGFR inhibitors alone or combined with cetuximab seemed to be more efficacious for mCRC respectively; however, the effects were not better than FOLFOX4 alone or when combined with bevacizumab for mCRC. Additionally, selective VEGFR inhibitors were not as safe as placebo or FOLFOX4 alone or in combination with bevacizumab in mCRC.

Keywords: Metastatic colorectal cancer, chemotherapy, VEGFR inhibitor, Bevacizumab, meta-analysis, randomized controlled trials.

[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Siegel RL, Miller KD. Cancer statistics 2019; 69(1): 7-34.
[3]
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-87.
[http://dx.doi.org/10.1016/j.ejca.2018.07.005] [PMID: 30100160]
[4]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66(2): 115-32.
[http://dx.doi.org/10.3322/caac.21338] [PMID: 26808342]
[5]
Sineshaw HM, Robbins AS, Jemal A. Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States. Cancer Causes Control 2014; 25(4): 419-23.
[http://dx.doi.org/10.1007/s10552-014-0344-z] [PMID: 24445597]
[6]
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64(1): 9-29.
[http://dx.doi.org/10.3322/caac.21208] [PMID: 24399786]
[7]
Provenzale D, Jasperson K, Ahnen DJ, et al. Colorectal Cancer Screening, Version 1.2015. J Natl Compr Canc Netw 2015; 13(8): 959-68.
[http://dx.doi.org/10.6004/jnccn.2015.0116] [PMID: 26285241]
[8]
Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22(2): 229-37.
[http://dx.doi.org/10.1200/JCO.2004.05.113] [PMID: 14657227]
[9]
Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet 2016; 388(10043): 518-29.
[http://dx.doi.org/10.1016/S0140-6736(15)01088-0] [PMID: 26853587]
[10]
Goel G, Sun W. Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice. J Hematol Oncol 2015; 8: 92.
[http://dx.doi.org/10.1186/s13045-015-0183-8] [PMID: 26215324]
[11]
Tampellini M, Sonetto C, Scagliotti GV. Novel anti-angiogenic therapeutic strategies in colorectal cancer. Expert Opin Investig Drugs 2016; 25(5): 507-20.
[http://dx.doi.org/10.1517/13543784.2016.1161754] [PMID: 26938715]
[12]
Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12): 2013-9.
[http://dx.doi.org/10.1200/JCO.2007.14.9930] [PMID: 18421054]
[13]
Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43(3): 490-501.
[http://dx.doi.org/10.1345/aph.1L426] [PMID: 19261963]
[14]
Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013; 31(30): 3791-9.
[http://dx.doi.org/10.1200/JCO.2012.47.4940] [PMID: 24019545]
[15]
Sun Q, Zhou J, Zhang Z, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther 2014; 15(12): 1635-45.
[http://dx.doi.org/10.4161/15384047.2014.964087] [PMID: 25482937]
[16]
Moore K, Infante JR, Cotreau MM, et al. A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors. Clin Pharmacol Drug Dev 2014; 3(4): 284-9.
[http://dx.doi.org/10.1002/cpdd.113] [PMID: 27128834]
[17]
Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008; 14(22): 7272-83.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0652] [PMID: 19010843]
[18]
Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012; 30(29): 3588-95.
[http://dx.doi.org/10.1200/JCO.2012.42.5355] [PMID: 22965961]
[19]
Infante JR, Reid TR, Cohn AL, et al. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. Cancer 2013; 119(14): 2555-63.
[http://dx.doi.org/10.1002/cncr.28112] [PMID: 23605883]
[20]
Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol 2017; 10(1): 22.
[http://dx.doi.org/10.1186/s13045-016-0384-9] [PMID: 28103904]
[21]
Grávalos C, Carrato A, Tobeña M, et al. A randomized phase II study of axitinib as maintenance therapy after first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 2018; 17(2): e323-9.
[http://dx.doi.org/10.1016/j.clcc.2018.02.004] [PMID: 29551560]
[22]
Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the fresco randomized clinical trial. JAMA 2018; 319(24): 2486-96.
[http://dx.doi.org/10.1001/jama.2018.7855] [PMID: 29946728]
[23]
Liao X, Li H, Liu Z, et al. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment. Medicine (Baltimore) 2018; 97(50)e13635
[http://dx.doi.org/10.1097/MD.0000000000013635] [PMID: 30558053]
[24]
Bendell JC, Tournigand C, Swieboda-Sadlej A, et al. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Clin Colorectal Cancer 2013; 12(4): 239-47.
[http://dx.doi.org/10.1016/j.clcc.2013.09.001] [PMID: 24188685]
[25]
Cunningham D, Wong RP, D’Haens G, et al. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br J Cancer 2013; 108(3): 493-502.
[http://dx.doi.org/10.1038/bjc.2012.545] [PMID: 23299530]
[26]
Benson AB III, Kiss I, Bridgewater J, et al. BATON-CRC: A phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer. Clin Cancer Res 2016; 22(20): 5058-67.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-3117] [PMID: 27401244]
[27]
Hecht JR, Trarbach T, Hainsworth JD, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29(15): 1997-2003.
[http://dx.doi.org/10.1200/JCO.2010.29.4496] [PMID: 21464406]
[28]
Kato T, Muro K, Yamaguchi K, et al. Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. Ann Oncol 2012; 23(4): 933-41.
[http://dx.doi.org/10.1093/annonc/mdr359] [PMID: 21828378]
[29]
Van Cutsem E, Bajetta E, Valle J, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29(15): 2004-10.
[http://dx.doi.org/10.1200/JCO.2010.29.5436] [PMID: 21464401]
[30]
Hoff PM, Hochhaus A, Pestalozzi BC, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 2012; 30(29): 3596-603.
[http://dx.doi.org/10.1200/JCO.2012.42.6031] [PMID: 22965965]
[31]
Galal KM, Khaled Z, Mourad AMM. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. Indian J Cancer 2011; 48(1): 47-54.
[http://dx.doi.org/10.4103/0019-509X.75825] [PMID: 21248446]
[32]
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381(9863): 303-12.
[http://dx.doi.org/10.1016/S0140-6736(12)61900-X] [PMID: 23177514]
[33]
Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 2013; 31(10): 1341-7.
[http://dx.doi.org/10.1200/JCO.2012.45.1930] [PMID: 23358972]
[34]
Tabernero J, Garcia-Carbonero R, Cassidy J, et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial Clinical cancer research an official journal of the American Association for Cancer Research> 2013; 19(9): 2541-50..
[35]
Siu LL, Shapiro JD, Jonker DJ, et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol 2013; 31(19): 2477-84.
[http://dx.doi.org/10.1200/JCO.2012.46.0543] [PMID: 23690424]
[36]
O’Neil BH, Cainap C, Van Cutsem E, et al. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. Clin Colorectal Cancer 2014; 13(3): 156-163.e2.
[http://dx.doi.org/10.1016/j.clcc.2014.04.001] [PMID: 25066269]
[37]
Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16(6): 619-29.
[http://dx.doi.org/10.1016/S1470-2045(15)70156-7] [PMID: 25981818]
[38]
Van Cutsem E, Yoshino T, Lenz HJ, et al. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann Oncol 2018; 29(9): 1955-63.
[http://dx.doi.org/10.1093/annonc/mdy241] [PMID: 30010751]
[39]
Sanoff HK, Goldberg RM, Ivanova A, et al. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer 2018; 124(15): 3118-26.
[http://dx.doi.org/10.1002/cncr.31552] [PMID: 29905927]
[40]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[41]
Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007; 6(2): 175-82.
[http://dx.doi.org/10.1517/14740338.6.2.175] [PMID: 17367263]
[42]
Geng R, Song L, Li J, Zhao L. The safety of apatinib for the treatment of gastric cancer. Expert Opin Drug Saf 2018; 17(11): 1145-50.
[http://dx.doi.org/10.1080/14740338.2018.1535592] [PMID: 30324820]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 26
Year: 2020
Page: [3171 - 3186]
Pages: 16
DOI: 10.2174/1381612826666200218095932
Price: $65

Article Metrics

PDF: 33
HTML: 2